前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果

江涛 廖英坚

[摘要]目的 探討前列地尔治疗冠状动脉粥样硬化性心脏病患者的临床效果。方法 选取2016年10月～2018年10月我院收治的50例冠状动脉粥样硬化性心脏病患者作为研究对象，按照随机数字表法分为观察组（25例）和对照组（25例）。观察组采用前列地尔治疗，对照组采用硝酸甘油治疗。比较两组的临床治疗效果、心功能相关指标及治疗前后的血脂水平。结果 观察组的治疗总有效率高于对照组，差异有统计学意义（P<0.05）。观察组的每搏心输出量（SV）高于对照组，心率（HR）低于对照组，差异均有统计学意义（P<0.05）。治疗前，两组的血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）及高密度脂蛋白胆固醇（HDL-C）水平比较，差异无统计学意义（P>0.05）;治疗后，两组的TC、TG、LDL-C水平低于治疗前，HDL-C水平高于治疗前，观察组的TC、TG、LDL-C水平低于对照组，HDL-C水平高于对照组，差异均有统计学意义（P<0.05）。结论 对冠状动脉粥样硬化性心脏病患者采用前列地尔治疗，能提高治疗效果，改善心功能指标及血脂水平，值得临床推广应用。

[关键词]前列地尔;冠状动脉粥样硬化性心脏病;临床效果;心功能

[中图分类号] R714.252          [文献标识码] A          [文章编号] 1674-4721（2020）2（c）-0076-03

Clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease

JIANG Tao   LIAO Ying-jian

Department of Cardiovascular Medicine， the Second People′s Hospital of Pingxiang City， Jiangxi Province， Pingxiang   337000， China

[Abstract] Objective To explore the clinical effect of Alprostadil in the treatment of patients with coronary atherosclerotic heart disease. Methods Fifty patients with coronary atherosclerotic heart disease treated in our hospital from October 2016 to October 2018 were selected as the research subjects， they were divided into the observation group （25 cases） and the control group （25 cases） according to the random number table method. The observation group was treated with Alprostadil， the control group was treated with Nitroglycerin. The clinical treatment effects， cardiac function-related indicators， and blood lipid levels before and after treatment were compared between the two groups. Results The total effective rate of treatment in the observation group was higher than that in the control group， the difference was statistically significant （P<0.05）. The cardiac output （SV） of the observation group was higher than that of the control group，  the heart rate （HR） was lower than that of the control group， the differences were statistically significant （P<0.05）. Before treatment， there were no significant differences in serum total cholesterol （TC）， triacylglycerol （TG）， low density lipoprotein cholesterol （LDL-C）， and high density lipoprotein cholesterol （HDL-C） between the two groups （P>0.05）. After treatment， the levels of TC， TG， and LDL-C in the two groups were lower than those of before treatment， the levels of HDL-C was higher than that of before treatment， the levels of TC， TG， LDL-C in the observation group were lower than those in the control group， the levels of HDL-C was higher than that in the control group， the differences were statistically significant （P<0.05）. Conclusion The use of Alprostadil in patients with coronary atherosclerotic heart disease can improve the treatment effect， improve cardiac function indicators and blood lipid levels， which is worthy of clinical application.